PAHC vs IDXX

For growth investors, Phibro Animal Health Corporation (PAHC) is the stronger pick with 27.

4% revenue growth year-over-year, versus 10. 4% for IDEXX Laboratories, Inc. (IDXX). Phibro Animal Health Corporation (PAHC) offers the better valuation at 36. 3x trailing P/E (14. 2x forward), making it the more compelling value choice. Analysts rate Phibro Animal Health Corporation (PAHC) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Phibro Animal Health Corporation (PAHC) is the cheapest at 36.

3x versus IDEXX Laboratories, Inc. at 43. 7x. On forward P/E, Phibro Animal Health Corporation is actually cheaper at 14. 2x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Phibro Animal Health Corporation wins at 1. 90x versus IDEXX Laboratories, Inc. 's 2. 76x — a reasonable growth-adjusted valuation.

Over the past 5 years, Phibro Animal Health Corporation (PAHC) delivered a total return of +66.

0%, compared to +5. 1% for IDEXX Laboratories, Inc. (IDXX). Over 10 years, the gap is even starker: IDXX returned +556. 2% versus PAHC's +128. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), IDEXX Laboratories, Inc.

(IDXX) is the lower-risk stock at 1. 35β versus Phibro Animal Health Corporation's 1. 38β — meaning PAHC is approximately 2% more volatile than IDXX relative to the S&P 500. On balance sheet safety, IDEXX Laboratories, Inc. (IDXX) carries a lower debt/equity ratio of 67% versus 3% for Phibro Animal Health Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Phibro Animal Health Corporation (PAHC) is pulling ahead at 27.

4% versus 10. 4% for IDEXX Laboratories, Inc. (IDXX). On earnings-per-share growth, the picture is similar: Phibro Animal Health Corporation grew EPS 1883% year-over-year, compared to 22. 6% for IDEXX Laboratories, Inc.. Over a 3-year CAGR, PAHC leads at 11. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

IDEXX Laboratories, Inc.

(IDXX) is the more profitable company, earning 24. 6% net margin versus 3. 7% for Phibro Animal Health Corporation — meaning it keeps 24. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IDXX leads at 31. 6% versus 8. 5% for PAHC. At the gross margin level — before operating expenses — IDXX leads at 61. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Phibro Animal Health Corporation (PAHC) is the more undervalued stock at a PEG of 1. 90x versus IDEXX Laboratories, Inc. 's 2. 76x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Phibro Animal Health Corporation (PAHC) trades at 14. 2x forward P/E versus 39. 5x for IDEXX Laboratories, Inc. — 25. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IDXX: 35. 1% to $773. 13.

In this comparison, PAHC (1.

1% yield) pays a dividend. IDXX does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Phibro Animal Health Corporation (PAHC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (1.

1% yield, +128. 6% 10Y return). Both have compounded well over 10 years (PAHC: +128. 6%, IDXX: +556. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PAHC is a small-cap high-growth stock; IDXX is a mid-cap quality compounder stock. PAHC pays a dividend while IDXX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.